Skip to main content

MRI Contrast Agents: Advancing Diagnostic Imaging

Page 1

01 · TITLE & MARKET LANDSCAPE

Industry Report · Healthcare & Medical Imaging · 2025–2035

Magnetic Resonance Imaging (MRI) Contrast Agent Market Macrocyclic chemistries and prefilled formats drive a USD 4.90 Billion market by 2035

Executive Summary • Market valued at USD 2.30 Bn in 2025; set to more

than double to USD 4.90 Bn by 2035. • 7.9% CAGR (2026–2035) creates a USD 2.42 Bn absolute dollar opportunity. • Gadolinium-based agents hold ~90%; North America leads with ~34% share. • Regulation favors diversified, macrocyclic-ready suppliers as safety scrutiny intensifies. MARKET SIZE 2025

FORECAST 2035

CAGR 2026–2035

NEW OPPORTUNITY

$2.30 Bn

$4.90 Bn

7.9%

$2.42 Bn

Base year value

From $2.48 Bn in 2026

Broad-based growth

Absolute $ gain to 2035

Market Size Trajectory (USD Bn)

Leading Segment Shares (2025)

4.90 2.30

2025

2.48

7.9% CAGR →

2026

2035

Gadolinium-Based Agents

~90%

Intravenous Route

~88%

Hospitals (End User)

~54%

North America (Region)

~34%

Central Nervous System

~34%

Industry Ecosystem Overview Chemistries

Formats

Channels

End Users

Gadolinium, iron-based, oral

Vials ~55%; prefilled

Originator direct ~40%;

Hospitals, imaging &

enteric, manganese

syringes fastest at 10.2%

private label 11.5% CAGR

ambulatory centers, academia

Copyright © Next Move Strategy Consulting

Source: Next Move Strategy Consulting, MRI Contrast Agent Market Report


02 · GROWTH DRIVERS & OPPORTUNITIES

What is expanding demand through 2035

Disease burden and MRI capacity expansion add ~3.7 points to market CAGR Six structural drivers outweigh safety, cost and regulatory restraints across the 2026–2035 forecast.

Impact on CAGR (+/− %), 2026–2035

Driver Restraint

+2.0%

Rising cancer & neurological disease burden

+1.7%

Expanding MRI installed base & volumes

+1.5%

Imaging infrastructure build-out in APAC

+1.3%

Regulatory shift to macrocyclic agents

+1.0%

Adoption of prefilled syringe formats

+0.8%

Pediatric & oncology imaging protocols

−1.1%

Gadolinium retention & NSF safety concerns

−0.7%

High macrocyclic cost in price-sensitive markets

−0.5%

Stringent regulatory review timelines

Fastest-Growing Sub-Segments Sub-segment

Axis

CAGR

Other & Emerging Agents

Product

13.0%

Private Label

Channel

11.5%

Pediatric Imaging

Application

10.4%

Prefilled Syringe

Pack Format

10.2%

Imaging Centers

End User

9.5%

Oral Enteric

Route

9.5%

CNS imaging is the largest application at USD 0.78 Bn (2025), growing to USD 1.60 Bn by 2035 at 8.3% CAGR.

Key Emerging Trends Macrocyclic Shift

Prefilled Syringes

AI Dose Optimization

Pediatric Formulations

Formularies favor lower-

Dosing precision and faster

AI reconstruction enables

Labeling expansions and

retention chemistries; Bayer

prep make it a premium,

diagnostic images at reduced

weight-based dosing formats

filed low-dose gadoquatrane

higher-margin format.

gadolinium doses.

for younger patients.

with FDA (Jun 2025).

Copyright © Next Move Strategy Consulting

Source: Next Move Strategy Consulting, MRI Contrast Agent Market Report


03 · REGIONAL OPPORTUNITIES

Where the next USD 2.42 Bn of demand will come from

Asia-Pacific overtakes North America as the largest region by 2035 APAC grows from USD 0.60 Bn to USD 1.61 Bn at an 11.6% CAGR, while North America remains the 2025 leader.

Region

2025

2035

CAGR

Key Driver

North America

$0.78 Bn

$1.46 Bn

7.2%

Mature infrastructure; FDA labeling-driven macrocyclic adoption

Europe

$0.62 Bn

$1.17 Bn

7.3%

EMA guidance and reformulation mandates

Asia-Pacific

$0.60 Bn

$1.61 Bn

11.6%

Expanding MRI installed base; rising imaging spend

Middle East & Africa

$0.16 Bn

$0.36 Bn

9.4%

Vision 2030-linked healthcare diversification

Latin America

$0.14 Bn

$0.29 Bn

8.7%

Growing imaging consumption; expanding hospital networks

Country Hotspots

Whitespace Opportunities

U.S. · LARGEST

INDIA · FASTEST

$563 Mn

16.0%

2025 market value

CAGR 2026–2035

• Dose-optimized macrocyclics for hospital radiology seeking lower cumulative gadolinium exposure. • Cost-efficient agents for APAC & LATAM imaging centers via distributor and tender contracts.

BRAZIL

ARGENTINA

$69 → $144 Mn

$21 → $42 Mn

8.5% CAGR

8.0% CAGR

Copyright © Next Move Strategy Consulting

• Manganese-based alternatives for renally impaired patients facing NSF risk.

Source: Next Move Strategy Consulting, MRI Contrast Agent Market Report


04 · COMPETITIVE SCENARIO

Leading companies, positioning and strategic moves

Moderately consolidated: global originators lead, regional producers win on cost Top profiled companies hold a majority of revenue; APAC producers serve cost-sensitive gadolinium demand. Competitive Positioning Matrix NEXT-GEN INNOVATORS

Portfolio breadth & innovation →

Gadolinium-free, nano platforms

Market Structure DIVERSIFIED GLOBAL ORIGINATORS

20

Macrocyclic & pipeline leaders

Spago Nanomedical Nano Therapeutics

Bayer AG

GE HealthCare

Bracco Imaging

Guerbet

38

countries covered

companies profiled

• Market share data available for the top 10 companies. • Innovation pipelines center on

REGIONAL COST LEADERS

PORTFOLIO BROADENERS

macrocyclic reformulation, prefilled

Tender-driven gadolinium supply

Generics & licensing-led reach

syringes and manganese-based

Jiangsu Hengrui

Zydus Lifesciences

agents.

Beijing Beilu

Hikma Pharmaceuticals

• Safety scrutiny favors diversified, regulation-ready suppliers over single-agent specialists. TWO DOMINANT ARCHETYPES Diversified global originators vs.

Geographic & channel reach →

specialized regional cost-leadership manufacturers.

Illustrative positioning based on NMSC competitive archetypes; not a market-share ranking.

Recent Strategic Moves JUN 2025 · REGULATORY

APR 2026 · PIPELINE

LICENSING · PARTNERSHIP

EXPANSION · CAPACITY

Bayer AG

GE HealthCare

Submitted low-dose

First patient dosed in Phase 2/3

Zydus Lifesciences

Expanding prefilled syringe

macrocyclic gadoquatrane to

LUMINA trial of manganese-

Exclusive licensing & supply

portfolios; GE's 14-year Care

FDA; program includes pediatric

based mangaciclanol (FDA Fast

deal with Viwit Pharmaceuticals

Alliance extends hospital

patients.

Track).

broadens U.S. gadolinium

network reach.

Bracco & Guerbet

portfolio.

Key Strategies & Implications Expansion

Partnerships & M&A

Pipeline Innovation

APAC fill-finish and prefilled syringe

Selective licensing and supply

Low-dose macrocyclics, pediatric labels

assembly capacity; long-term hospital

agreements to add products and enter

and gadolinium-free manganese agents.

alliances.

new markets.

Copyright © Next Move Strategy Consulting

Source: Next Move Strategy Consulting, MRI Contrast Agent Market Report


05 · THANK YOU & CONTACT

Connect with our healthcare research team

Thank You Connect with us for in-depth MRI contrast agent insights, segment-level forecasts and strategic guidance tailored to your investment or growth plans.

$4.90 Bn

7.9% CAGR

11.6%

Market size by 2035

2026–2035 growth outlook

Asia-Pacific CAGR, fastest region

WEBSITE

PHONE

www.nextmsc.com

EMAIL

+1 857 758 5017

info@nextmsc.com

Get the complete MRI Contrast Agent Market report

Click here for the report →

20 company profiles · 38 countries · top-10 market shares

Follow Us

LinkedIn

Facebook

YouTube

Twitter / X

Instagram

Market intelligence for investors, strategy teams and B2B decision-makers

Copyright © Next Move Strategy Consulting

www.nextmsc.com


Turn static files into dynamic content formats.

Create a flipbook
MRI Contrast Agents: Advancing Diagnostic Imaging by bhryh345y - Issuu